Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.
- First patient in TRP-8803 Phase 2 BED trial shows multi-domain symptom improvement
- Cohort 1 fully enrolled with dosing progressing and reproducible psychedelic responses
- Peer-reviewed Phase 2a TRP-8802 data confirms rapid, sustained binge eating reductions
- Australian patent granted for precision-controlled IV dosing method extending protection to 2042
- Received $1.73 million R&D tax incentive refund; $9.1 million cash and facilities available
Early Clinical Validation of TRP-8803 in Binge Eating Disorder
Entropy Neurodynamics (ASX:ENP) delivered a significant milestone in its clinical development with the first patient treated in its Phase 2 trial of TRP-8803, an intravenous psilocin formulation targeting Binge Eating Disorder (BED). The patient demonstrated clinically meaningful improvements across a spectrum of symptoms including binge eating severity, anxiety, depression, body image satisfaction, and overall wellbeing at the four-week post-treatment assessment. This early success exceeded clinical investigators' expectations and offers initial validation for the precision-controlled IV psilocin platform.
The trial, conducted in partnership with Swinburne University, has now completed enrolment of its first cohort of six patients. Dosing has advanced steadily, with the first three patients having completed treatment and exhibiting consistent and reproducible psychedelic responses. These controlled responses underscore TRP-8803’s key advantage over oral psilocybin therapies by enabling precise control over onset, intensity, and duration of the psychedelic experience, which is central to the company’s commercial strategy.
Supporting Clinical Data from Oral Psilocybin Trial Strengthens Development
Complementing the TRP-8803 program, Entropy published peer-reviewed Phase 2a results for its oral psilocybin candidate, TRP-8802, in the Journal of Eating Disorders. Conducted alongside the University of Florida, the study showed rapid and sustained reductions in binge eating episodes in all evaluable patients, with an average 80% reduction maintained through 14 weeks. Severe BED cases dropped from 40% at baseline to zero by Week 6, with 80% of patients classified as none-to-mild by Week 14.
Secondary outcomes revealed meaningful improvements in anxiety, depression, psychological flexibility, and metabolic markers such as waist circumference, supported by exploratory neuroimaging suggesting enhanced cognitive control over compulsive behaviours. This data not only validates the therapeutic approach but also directly supports the advancement of TRP-8803 as a next-generation, scalable treatment.
Patent Grant Secures Long-Term Competitive Advantage
In a strategic boost to its intellectual property portfolio, Entropy secured an Australian patent covering its precision-controlled, two-phase intravenous dosing method for psilocin and related compounds. This patent extends protection through to 2042 and includes claims over multiple delivery routes and neuropsychiatric indications, reinforcing a strong barrier to entry.
Notably, the patent incorporates EEG-based monitoring technology, positioning Entropy at the forefront of precision psychiatry and supporting the development of objective biomarkers crucial for future clinical and regulatory pathways. This patent grant aligns with the company’s broader platform strategy and enhances its attractiveness to potential strategic partners as it progresses clinical development.
Financial Position and Use of Funds Reflect Expanding Clinical Activities
Entropy’s financial footing remains solid with $9.1 million in cash, equivalents, and funding facilities as of 31 March 2026. The company received a $1.73 million R&D tax incentive refund for FY25, representing a 48.5% offset on eligible expenditures, which supports ongoing clinical programs. During the quarter, Entropy repaid $650,000 of its R&D loan facility, retaining access to $2.6 million in non-dilutive funding.
Use of funds has exceeded initial prospectus estimates, driven by an expanded clinical program that includes an additional cohort in the TRP-8803 study, investment in EEG equipment to reduce future trial costs, and the initiation of the IV BED trial at Swinburne University. Capital raising costs also increased due to multiple funding rounds, reflecting the company’s active financing strategy to underpin clinical development.
Next Steps in Clinical Development and Broader Trial Plans
Entropy plans to complete dosing and follow-up for all six patients in Cohort 1 this quarter, with top-line results expected thereafter. The company is preparing to advance into Cohort 2 and intends to launch additional clinical trial initiatives within the same timeframe, aiming to build on the early clinical validation of TRP-8803.
These developments follow Entropy’s recent milestone of dosing its third patient with TRP-8803 and observing full psychedelic responses, reinforcing the drug’s potential for precise therapeutic delivery third patient dosing progress. Moreover, the receipt of the $1.73 million R&D tax incentive refund underscores continued government support for the company’s innovative approach R&D tax incentive refund. The patent protection further solidifies Entropy’s position in the emerging psychedelic therapeutics space patent grant details.
Bottom Line?
Entropy’s early clinical data and strengthened patent position position TRP-8803 as a promising precision psychedelic therapy, but upcoming cohort results will be pivotal for validating its commercial potential.
Questions in the middle?
- Will full Cohort 1 data confirm the early symptomatic improvements seen in the first patient?
- How will Entropy leverage its patent portfolio to attract strategic partnerships or licensing deals?
- What are the timelines and design for the broader clinical trial initiatives planned this quarter?